Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Top Cited Papers
- 1 July 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 380 (9839), 358-365
- https://doi.org/10.1016/s0140-6736(12)60868-x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Abstract 4837: Tumor microenvironment contributes to RAF-inhibitor resistance through HGF secretionCancer Research, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002